Reduced-intensity stem cell transplantation for hematological malignancies

Current status and the future

Koji Kato, Yasser Khaled, Shin Mineishi

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Reduced-intensity stem cell transplantation (RIST) has opened a new era for hematopoietic stem cell transplantation (HSCT). It was developed based on the knowledge that graft-versus-tumor (GVT) effect is the main anti-tumor effect in allogeneic HSCT. Because RIST is associated with less morbidity and mortality, it can be applied to many patients who could not undergo conventional HSCT. Experiences in the last decade clarified many issues related to RIST. For example, graft-versus-host disease (GVHD) in RIST may differ in character compared to conventional HSCT. Also, it is now known that intensity of conditioning is important in disease control, and the optimal regimens may be different for each disease or for each disease status. There are still many unsolved questions, and large prospective randomized trials are necessary to resolve these.

Original languageEnglish (US)
Pages (from-to)149-162
Number of pages14
JournalCurrent Stem Cell Research and Therapy
Volume2
Issue number2
DOIs
StatePublished - May 1 2007
Externally publishedYes

Fingerprint

Hematopoietic Stem Cell Transplantation
Stem Cell Transplantation
Hematologic Neoplasms
Graft vs Host Disease
Neoplasms
Morbidity
Transplants
Mortality

All Science Journal Classification (ASJC) codes

  • Medicine (miscellaneous)

Cite this

Reduced-intensity stem cell transplantation for hematological malignancies : Current status and the future. / Kato, Koji; Khaled, Yasser; Mineishi, Shin.

In: Current Stem Cell Research and Therapy, Vol. 2, No. 2, 01.05.2007, p. 149-162.

Research output: Contribution to journalReview article

@article{94c3352d0d4844b39c06c1c61e5a9afe,
title = "Reduced-intensity stem cell transplantation for hematological malignancies: Current status and the future",
abstract = "Reduced-intensity stem cell transplantation (RIST) has opened a new era for hematopoietic stem cell transplantation (HSCT). It was developed based on the knowledge that graft-versus-tumor (GVT) effect is the main anti-tumor effect in allogeneic HSCT. Because RIST is associated with less morbidity and mortality, it can be applied to many patients who could not undergo conventional HSCT. Experiences in the last decade clarified many issues related to RIST. For example, graft-versus-host disease (GVHD) in RIST may differ in character compared to conventional HSCT. Also, it is now known that intensity of conditioning is important in disease control, and the optimal regimens may be different for each disease or for each disease status. There are still many unsolved questions, and large prospective randomized trials are necessary to resolve these.",
author = "Koji Kato and Yasser Khaled and Shin Mineishi",
year = "2007",
month = "5",
day = "1",
doi = "10.2174/157488807780599248",
language = "English (US)",
volume = "2",
pages = "149--162",
journal = "Current Stem Cell Research and Therapy",
issn = "1574-888X",
publisher = "Bentham Science Publishers B.V.",
number = "2",

}

TY - JOUR

T1 - Reduced-intensity stem cell transplantation for hematological malignancies

T2 - Current status and the future

AU - Kato, Koji

AU - Khaled, Yasser

AU - Mineishi, Shin

PY - 2007/5/1

Y1 - 2007/5/1

N2 - Reduced-intensity stem cell transplantation (RIST) has opened a new era for hematopoietic stem cell transplantation (HSCT). It was developed based on the knowledge that graft-versus-tumor (GVT) effect is the main anti-tumor effect in allogeneic HSCT. Because RIST is associated with less morbidity and mortality, it can be applied to many patients who could not undergo conventional HSCT. Experiences in the last decade clarified many issues related to RIST. For example, graft-versus-host disease (GVHD) in RIST may differ in character compared to conventional HSCT. Also, it is now known that intensity of conditioning is important in disease control, and the optimal regimens may be different for each disease or for each disease status. There are still many unsolved questions, and large prospective randomized trials are necessary to resolve these.

AB - Reduced-intensity stem cell transplantation (RIST) has opened a new era for hematopoietic stem cell transplantation (HSCT). It was developed based on the knowledge that graft-versus-tumor (GVT) effect is the main anti-tumor effect in allogeneic HSCT. Because RIST is associated with less morbidity and mortality, it can be applied to many patients who could not undergo conventional HSCT. Experiences in the last decade clarified many issues related to RIST. For example, graft-versus-host disease (GVHD) in RIST may differ in character compared to conventional HSCT. Also, it is now known that intensity of conditioning is important in disease control, and the optimal regimens may be different for each disease or for each disease status. There are still many unsolved questions, and large prospective randomized trials are necessary to resolve these.

UR - http://www.scopus.com/inward/record.url?scp=34249657929&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249657929&partnerID=8YFLogxK

U2 - 10.2174/157488807780599248

DO - 10.2174/157488807780599248

M3 - Review article

VL - 2

SP - 149

EP - 162

JO - Current Stem Cell Research and Therapy

JF - Current Stem Cell Research and Therapy

SN - 1574-888X

IS - 2

ER -